KRAS and Miyoshi myopathy: In addition to cancer Hallmark pathways, KRAS signaling is upregulated in R/R MMs but downregulated in ND MMs (Figure 1C), indicating KRAS-mediated oncogenic signaling activation in MM progression (27).